0.35
前日終値:
$0.3577
開ける:
$0.36
24時間の取引高:
184.26K
Relative Volume:
1.18
時価総額:
$22.93M
収益:
-
当期純損益:
$-68.80M
株価収益率:
-0.2991
EPS:
-1.17
ネットキャッシュフロー:
$-59.06M
1週間 パフォーマンス:
-5.15%
1か月 パフォーマンス:
-30.15%
6か月 パフォーマンス:
-40.78%
1年 パフォーマンス:
-69.30%
Passage Bio Inc Stock (PASG) Company Profile
名前
Passage Bio Inc
セクター
電話
(267) 866-0312
住所
ONE COMMERCE SQUARE, PHILADELPHIA, PA
PASG を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PASG
Passage Bio Inc
|
0.35 | 22.93M | 0 | -68.80M | -59.06M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-29 | 再開されました | Wedbush | Outperform |
2024-09-03 | 開始されました | Rodman & Renshaw | Buy |
2022-03-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2022-01-19 | ダウングレード | Goldman | Buy → Neutral |
2021-07-01 | 開始されました | Raymond James | Outperform |
2021-06-15 | 開始されました | BTIG Research | Buy |
2021-03-04 | アップグレード | Goldman | Neutral → Buy |
2021-02-04 | 開始されました | Guggenheim | Buy |
2021-01-25 | 開始されました | Wedbush | Outperform |
2021-01-04 | アップグレード | JP Morgan | Neutral → Overweight |
2020-12-11 | 開始されました | Citigroup | Neutral |
2020-08-14 | ダウングレード | JP Morgan | Overweight → Neutral |
2020-06-25 | ダウングレード | Goldman | Buy → Neutral |
2020-03-25 | 開始されました | Chardan Capital Markets | Buy |
2020-03-24 | 開始されました | Cowen | Outperform |
2020-03-24 | 開始されました | Goldman | Buy |
2020-03-24 | 開始されました | JP Morgan | Overweight |
すべてを表示
Passage Bio Inc (PASG) 最新ニュース
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Fierce Biotech Layoff Tracker 2025: Mural lays off 90%; Pfizer sells site, cuts staff - Fierce Biotech
Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World
PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India
Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa
Passage Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
PASSAGE BIO, INC. Full Year Loss Decreases - Nasdaq
Passage Bio Reports 2024 Financial Results and Program Advances - TipRanks
Passage Bio Inc (PASG) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):